Respiratory Syncytial Virus Market Size in the 7MM was ~USD 1,300 Million in 2023 and is Expected to Grow Significantly Through 2034, with BEYFORTUS, AREXVY, and ABRYSVO Leading the Way, Estimates DelveInsight

DelveInsight's "Respiratory Syncytial Virus Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of RSV, historical and forecasted epidemiology as well as the RSV therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Discover Key Insights into the Respiratory Syncytial Virus Market with DelveInsight's In-Depth Report @ Nirsevimab Market Size - https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Key Takeaways from the Respiratory Syncytial Virus Market Report
• In April 2025, Pfizer announced that the European Commission approved an amendment to ABRYSVO's marketing authorization, expanding its indication to include the prevention of RSV-associated lower respiratory tract disease in adults aged 18 to 59 years.
• In March 2025, Clover Biopharmaceuticals announced FDA IND clearance and completion of first participant enrollment in a Phase I clinical trial evaluating SCB-1019, its non-adjuvanted bivalent RSV prefusion-stabilized F Trimer subunit vaccine candidate.
• In November 2024, a UK judge ruled in favor of Pfizer over GSK in an RSV vaccine patent lawsuit, intensifying competition in the emerging blockbuster RSV vaccine market and diminishing GSK's prospects of restricting Pfizer's market entry.
• In March 2024, AstraZeneca and Sanofi's BEYFORTUS (nirsevimab) received approval in Japan for the prophylaxis of lower respiratory tract disease caused by RSV in all neonates, infants, and children entering their first RSV season, and in children at risk entering their second RSV season.
• According to DelveInsight's patient-based forecasting model, the total Respiratory Syncytial Virus Market Size in the 7MM was around USD 1,300 million in 2023, with the US accounting for approximately 71% of the total 7MM RSV market size.
• In 2023 was a turning point in the battle against RSV, with the FDA approving the world's first RSV vaccine - AREXVY (RSVPreF3; GlaxoSmithKline) - for individuals aged 60 years and older, followed by ABRYSVO (RSVpreF; Pfizer), which is also the only RSV vaccine recommended during pregnancy.
• In 2023, total RSV incident cases were approximately 8,600,000 in the 7MM, with the US accounting for ~56% of cases. RSV incident cases were highest in children below 5 years of age, accounting for nearly 50% of total 7MM cases (~2,800,000).
• Among EU4 and the UK, the UK accounted for the highest RSV market size in 2023, followed by Germany. Among all therapies, BEYFORTUS, AREXVY, and ABRYSVO are expected to have a major influence on the market throughout the forecast period 2024-2034.
• The Respiratory Syncytial Virus Companies include Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer, and others.
• Promising RSV Therapies include ABRYSVO (RSVpreF; Pfizer), BEYFORTUS (nirsevimab; AstraZeneca/Sanofi), AREXVY (RSVPreF3; GSK), mRNA-1345 (Moderna), VAC18193/Ad26.RSV.preF (Janssen), and others.

Stay ahead in the Respiratory Syncytial Virus Therapeutics Market with DelveInsight's Strategic Report @ AREXVY Market Size - https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Respiratory Syncytial Virus Epidemiology Segmentation in the 7MM
The epidemiology section provides historical, current, and forecasted RSV incidence scenarios across the 7MM - covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2020 to 2034.
• Total Respiratory Syncytial Virus Incident Cases
• Age-Specific Incident Cases (below 5 years, 5-64 years, 65 years and above)
• Severity-Specific RSV Incident Cases in Children
• Severity-Specific RSV Incident Cases in Adults
• Visit-Specific RSV Incident Cases (outpatient, emergency, hospitalization)

Download the report to understand which factors are driving RSV epidemiology trends @ RSV Prevalence - https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Respiratory Syncytial Virus Emerging Drugs
• mRNA-1345: Moderna
mRNA-1345 is a messenger RNA vaccine encoding for a prefusion F glycoprotein, designed to elicit a superior neutralizing antibody response against RSV. Moderna filed for regulatory approvals of mRNA-1345 for the prevention of RSV-associated lower respiratory tract disease and acute respiratory disease in adults aged 60 years and older. This vaccine represents a significant advancement in the application of mRNA platform technology to respiratory infectious diseases beyond COVID-19.
• VAC18193 (Ad26.RSV.preF): Janssen
VAC18193 is Janssen's investigational prophylactic RSV vaccine for adults aged 60 and older, leveraging its proprietary AdVac adenovector platform. The investigational vaccine contains the gene encoding the fusion protein of the RSV virus as its antigen, aiming to prevent RSV-mediated lower respiratory tract disease in the senior population.

Respiratory Syncytial Virus Market Outlook
RSV is a common respiratory virus that infects the nose, throat, lungs, and breathing passages. It spreads through respiratory droplets, contaminated surfaces, and contact and is so widespread that almost all children will have had an RSV infection by age 2. Supportive care - including hydration, clearing nasal obstruction, and nutritional support - was the mainstay of RSV bronchiolitis treatment until 2023, before the landmark launches of approved vaccines and monoclonal antibodies.

The RSV treatment landscape underwent a fundamental transformation in 2023, with AREXVY becoming the world's first approved RSV vaccine, followed immediately by ABRYSVO - the only RSV vaccine approved for use during pregnancy. BEYFORTUS (nirsevimab), the only single-dose RSV passive immunization for the broad infant population including healthy, preterm, and at-risk infants, has since received approvals in the EU, US, and Japan, representing a paradigm shift from treatment to prevention.

Despite these landmark approvals, significant unmet needs persist - particularly for clinically effective, safe, and cost-effective antiviral treatments and extended half-life monoclonal antibodies. Challenges include stringent safety requirements in pediatric and maternal populations and the need for broad population awareness, as RSV as a major public health issue remains under-recognized by parents and families worldwide.

"The Respiratory Syncytial Virus Market Size in the 7MM was ~USD 1,300 million in 2023, with BEYFORTUS, AREXVY, and ABRYSVO expected to be the major market drivers throughout the forecast period 2024-2034, as the RSV treatment paradigm shifts decisively toward prevention through vaccines and long-acting monoclonal antibodies."

Get In-Depth Knowledge on RSV Market Trends and Forecasts with DelveInsight @ VAC-18193 Market Size - https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Scope of the Respiratory Syncytial Virus Market Report
• Coverage: 7MM
• Study Period: 2020-2034
• Forecast Period: 2024-2034
• RSV Companies: Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer, and others
• RSV Therapies: ABRYSVO (RSVpreF; Pfizer), BEYFORTUS (nirsevimab; AstraZeneca/Sanofi), AREXVY (RSVPreF3; GSK), mRNA-1345 (Moderna), VAC18193 (Janssen), and others
• RSV Therapeutic Assessment: Current marketed vaccines and monoclonal antibodies, and emerging pipeline candidates
• Market Dynamics: Market drivers and barriers, SWOT and conjoint analysis, KOL views, and reimbursement landscape

Unlock Strategic Insights with DelveInsight's Comprehensive RSV Market Report @ RSV Market Drivers and Barriers - https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Table of Content
• Key Insights
• Report Introduction
• Respiratory Syncytial Virus (RSV) Market Overview at a Glance
• Executive Summary of Respiratory Syncytial Virus (RSV)
• Key Events
• Disease Background and Overview
• Methodology
• Epidemiology and Patient Population
• Patient Journey
• Marketed Products
• Emerging Therapies
• Respiratory Syncytial Virus (RSV) Seven Major Market Analysis
• Market Access and Reimbursement
• KOL Views
• Unmet Needs
• SWOT Analysis
• Appendix
• DelveInsight Capabilities
• Disclaimer
• About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: kkumar@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-market

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.